Zodol (Ketorolac)

Quick links to important sections

Zodol (Ketorolac)

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zodol (Ketorolac)

Property Description
Active ingredient Ketorolac tromethamine
Form Tablet, injectable solution, nasal spray, ophthalmic solution
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use Acute pain relief and inflammation reduction
Origin Synthetic (Pyrrolo-pyrrole group)

What Type of Medicine is Zodol (Ketorolac)?

Zodol is a synthetic medication containing the active compound Ketorolac tromethamine, classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This classification defines the drug's core function: to relieve pain and reduce inflammation without the use of steroid compounds.

The medication operates as a powerful analgesic and anti-inflammatory agent by inhibiting the cyclooxygenase (COX) enzyme system, thereby limiting the synthesis of prostaglandins. Clinically recognized for its high level of analgesic potency, Ketorolac is differentiated from many conventional NSAIDs. Ketorolac is specifically indicated for the short-term management of moderately severe acute pain.


Zodol’s Composition and General Purpose

The medication is a single-ingredient product, with Ketorolac tromethamine being the active substance, often supplied as a racemic mixture in various formulations. The availability of Ketorolac is notable for its diverse dosage forms and routes of administration, including the oral tablet, the injectable solution (for intravenous or intramuscular use), the nasal spray, and the ophthalmic solution (eye drops).

The general therapeutic purpose of Ketorolac is to provide rapid and effective pain control. Because of its strength, the medicine is often utilized as an opioid-sparing agent, acting as an alternative to narcotic painkillers in acute settings. This specialized positioning highlights the medicine's value in protocols where powerful, non-narcotic options are required.

Regulatory References

  1. Ketorolac Labeling (NIH/DailyMed)

What side effects are possible with Zodol (Ketorolac)?

Major Safety Information and Boxed Warnings

Zodol (Ketorolac) is a powerful nonsteroidal anti-inflammatory drug (NSAID) indicated for the short-term (not to exceed five days) management of moderately severe acute pain. Its use is associated with several serious risks, including those related to the cardiovascular and gastrointestinal systems.


  • Cardiovascular Risk: Like other NSAIDs, Ketorolac can increase the risk of serious cardiovascular thrombotic events, such as myocardial infarction (heart attack) and stroke, which can be fatal. This risk may occur early in treatment and may increase with the duration of use. The drug is contraindicated for treating peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.

  • Gastrointestinal Risk: Ketorolac can cause serious gastrointestinal adverse events, including bleeding, ulceration, and perforation of the stomach or intestines. These events can be fatal and may occur without warning symptoms at any time during therapy. The risk increases with higher doses, longer duration of use, and in older adults.

  • Renal and Bleeding Risk: The medication is contraindicated in patients with advanced renal impairment and those at high risk of bleeding due to its effect on kidney function and platelet inhibition. Use in labor and delivery is also contraindicated due to potential adverse effects on fetal circulation and uterine contractions.


Common Side Effects

Commonly reported side effects, typically affecting 1% to 10% of patients, include gastrointestinal issues (such as nausea, dyspepsia, and abdominal pain), headache, dizziness, and edema (swelling due to fluid retention). If any side effects become severe or persistent, contact your healthcare provider.

Overdose and Emergency Response

Documented Manifestations and Severe Outcomes

Ketorolac (Zodol) overdose information is based on the documented effects of acute Nonsteroidal Anti-inflammatory Drug (NSAID) over-ingestion, as specified in regulatory labeling. Overdose cases are most commonly associated with self-limiting clinical manifestations, including abdominal pain, nausea, vomiting, drowsiness, epigastric pain, and temporary renal dysfunction.

The official prescribing information also documents the risk of severe and potentially life-threatening outcomes. These may include Gastrointestinal bleeding, peptic ulcers, and the rare occurrence of acute renal failure, hypertension, respiratory depression, or coma. The possibility of anaphylactoid reactions is also recognized.

Emergency Actions Mandated by Regulation

Urgent medical attention is required immediately upon suspected overdose or the onset of severe symptoms. Regulators mandate that patients exhibiting serious manifestations must contact a healthcare professional, hospital emergency department, or regional Poison Control Centre.

Management is limited to symptomatic and supportive care, as official documents state that no specific antidote is known for Ketorolac. Interventions such as the administration of activated charcoal and an osmotic cathartic may be indicated, particularly if a large oral overdose is reported within a four-hour window of ingestion.

Therapeutic Uses of Zodol (Ketorolac)

What Zodol (Ketorolac) Treats: Main Uses and Benefits

The therapeutic application of Zodol (Ketorolac) is specifically targeted at providing symptomatic support for conditions involving significant pain and inflammation, emphasizing its role in acute care scenarios rather than chronic management.

Ketorolac is indicated for the short-term management of moderately severe acute pain. This use is considered relevant when short-term symptomatic assistance is needed for heightened discomfort and when symptoms create noticeable physiological strain.

The medicine is commonly used across conditions presenting with acute episodes of post-traumatic discomfort, pain following complex dental procedures, discomfort after surgical interventions (perioperative care), and temporary inflammation or itching in the ophthalmic domain. This broad support helps address symptom clusters that may become intense or disruptive.

“This medication is applied across domains where additional symptomatic support is needed, assisting with the temporary easing of discomfort associated with acute physiological stress.”


Quick Fact: Relief for Acute Pain and Inflammation

Zodol contributes to improved comfort during periods of heightened symptoms, offering supportive relief when pain and inflammation interfere with routine activities. It is applied in addressing symptomatic discomfort when short-term assistance is appropriate.

Eligibility and Restrictions for Use

Eligibility Scope

Ketorolac is officially restricted to the short-term management of moderately severe acute pain, with a total combined duration of use not to exceed five days. Use is generally permitted only for adults who do not meet exclusion criteria, as safety and effectiveness in pediatric patients are generally not established for systemic use.


Eligibility Status Key Population Exclusions (Contraindicated)
Must Not Use History of gastrointestinal bleeding or peptic ulcer disease; advanced renal impairment; suspected or confirmed cerebrovascular bleeding; known allergy to aspirin or other NSAIDs; third trimester of pregnancy, labor, delivery, and breastfeeding; concurrent use with other NSAIDs or probenecid.
Age-Related Rules & Restrictions Conditional Use Requirements
Pediatric Use Systemic use is not indicated in patients under 17 years due to unestablished safety and efficacy.
Older Adults Patients 65 years and older, those under 50 kg, or those with moderate renal impairment require a reduced maximum total daily dose as a required regulatory restriction.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Zodol (Ketorolac) is defined by official regulatory documentation and centers on the increased risk of hemorrhage, toxicity, or the reduction of co-administered medicine efficacy.

Formal Contraindications

Co-administration with several medicinal products is strictly contraindicated due to significant risks documented in regulatory labeling. This includes other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including aspirin, due to the cumulative risk of gastrointestinal (GI) toxicity. Use with Anticoagulants (e.g., Warfarin) and Pentoxifylline is prohibited because of the high risk of serious hemorrhage. Furthermore, Probenecid is contraindicated as it severely decreases Ketorolac clearance, leading to dangerously increased plasma concentrations and toxicity risk.

Exposure and Pharmacodynamic Interactions

Ketorolac is documented to reduce the renal clearance of both Lithium and Methotrexate, which can increase their plasma levels and risk of toxicity. Regarding pharmacodynamic interactions, co-administration with Diuretics or ACE Inhibitors/ARBs may reduce their efficacy and increase the risk of renal impairment, particularly in volume-depleted or elderly patients. The risk of GI bleeding is also elevated when combined with SSRIs or Alcohol, an interaction noted in official labeling.

Mechanism of Action

Inhibition of Key Molecular Mediators

This drug acts as a non-selective, reversible inhibitor of the Cyclooxygenase (COX) enzyme system, targeting both the COX-1 and COX-2 isoforms. By blocking the enzymes’ ability to process arachidonic acid, the mechanism significantly reduces the synthesis of prostaglandins (PGE extsubscript2) and other prostanoids. This core molecular action reduces the generation of prostanoids involved in mediating heightened physiological responses.


Dual Central and Peripheral Pathway Modulation

The mechanism influences the nociceptive signaling pathway at multiple points. Peripherally, the reduction in prostaglandins decreases the sensitization of nociceptors at peripheral sites. Crucially, the molecule can cross the Blood-Brain Barrier to inhibit COX enzymes centrally. This dual action modulates the nociceptive signaling cascade by both lowering the peripheral input and attenuating the central signal amplification.


Mechanistic Influence on Platelet Function

The unavoidable non-selective nature of the enzyme inhibition extends to COX-1 found in platelets. This engagement prevents the synthesis of Thromboxane A extsubscript2 (TXA extsubscript2), a prostanoid involved in platelet aggregation. This molecular step leads to a temporary and reversible inhibition of platelet aggregation, resulting in a functional consequence of altering the aggregation process.

Dosage and Administration Information

The use of Zodol (Ketorolac tromethamine) is governed by specific protocols regarding administration, dosing, and maximum duration of treatment.

Administration and Duration Rules

Ketorolac is available for intravenous (IV), intramuscular (IM), oral (tablet), intranasal, and ophthalmic administration. The total combined duration of use for the IV, IM, oral, and intranasal forms must not exceed 5 days in adults. The oral tablet is indicated only as a continuation of initial IV or IM therapy; it is not to be given as a starting dose.

Regimen Type Standard Adult Dose (<65 years) Max Daily Dose
IV/IM Multiple-Dose 30 mg every 6 hours 120 mg
Oral Continuation 20 mg once, then 10 mg every 4–6 hours 40 mg

Population-Specific Adjustments

Lower doses are required for certain patient groups. For adults 65 years and older, those with renal impairment, or patients weighing less than 50 kg, the dose must be adjusted.

  • Adjusted IV/IM Multiple-Dose: 15 mg every 6 hours (Maximum 60 mg/day).
  • Adjusted Oral Continuation: 10 mg once, then 10 mg every 4–6 hours (Maximum 40 mg/day).
  • Intravenous Administration: The IV bolus injection must be administered over no less than 15 seconds. The medicine is generally not indicated for use in pediatric patients.

Recent Clinical Evidence

Research evidence / Overview of studies for Zodol (Ketorolac)

Evidence for Use in Moderately Severe Acute Systemic Pain

This section will summarize the evidence structure in research exploring acute pain, primarily drawing from short-term Randomized Controlled Trials (RCTs) and systematic reviews, detailing the study populations and the specific outcomes measured in those trials (e.g., pain intensity and analgesic consumption).

The primary body of research consists of short-term Randomized Controlled Trials (RCTs) and comprehensive systematic reviews. These studies were used in research exploring how symptoms change over time for conditions associated with acute or disruptive episodes, particularly following surgery or after acute physical trauma. The research examined outcomes related to physical discomfort, including patient-reported scores and functional limitations. Studies monitored outcomes reflecting daily functioning or activity level and compared the usage of other prescribed painkillers that patients used during the observation period, where measurements indicated patterns related to lower concurrent pain medication usage in some observed populations.

Evidence for Use in Ocular Pain and Inflammation

This part outlines the research base supporting the topical ophthalmic solution, describing the types of clinical trials conducted, the specific ocular outcomes examined (e.g., pain scores and inflammation markers), and the patient groups studied (e.g., post-cataract surgery).

The ophthalmic solution was studied primarily through short- to intermediate-term Randomized Controlled Trials. The research focused on its use in periods of heightened symptom activity following common eye procedures. Studies monitored outcomes linked to inflammatory or irritative states in the eye and examined how the medication may affect temporary physiological imbalance, such as the maintenance of adequate pupil size during surgery.

Synthesis of Research Gaps and Uncertainties

This final section identifies the key areas where research remains inconsistent or limited, focusing on methodological heterogeneity across studies, the constraints of the trial duration, and other limitations identified in regulatory review.

A primary limitation is that follow-up durations were limited to the short-term treatment window (typically up to five days), meaning long-term effects are not fully established. Data for certain groups remain insufficient, especially in pediatric populations and those with multiple complex co-existing medical conditions. The study results reflect the specific conditions under which they were conducted, and research cannot predict whether an individual will respond similarly.

Key Studies & References

  1. Ketorolac and opioid sparing: a review of the literature.
  2. Topical nonsteroidal anti-inflammatory drugs versus corticosteroids for the prevention of cystoid macular edema after cataract surgery: a meta-analysis.

Frequently Asked Questions (FAQ)

Common questions about Zodol (Ketorolac) (FAQ)

Q: Is Zodol the same type of medicine as ibuprofen or naproxen?

A: Official documents classify Zodol (Ketorolac) as a non-steroidal anti-inflammatory drug (NSAID). Ibuprofen and naproxen belong to the same NSAID drug class, meaning they share a similar mechanism of action. However, Zodol is typically indicated for the short-term management of more severe, acute pain.


Q: Can Zodol cause stomach issues like other NSAIDs?

A: Yes, official warnings state that Zodol, similar to other NSAIDs, carries a risk of serious gastrointestinal issues, including bleeding, ulcers, and perforation. It has also been associated with less severe common issues like dyspepsia (indigestion) and abdominal discomfort. The risk of these adverse effects is a key reason for the drug’s strict short-term use limitation.


Q: Is Zodol safe for people with kidney problems?

A: Official regulatory warnings advise against the use of Zodol in patients who have advanced renal (kidney) impairment or who are at risk for kidney failure due to severe volume depletion. For individuals with existing kidney issues, official prescribing information indicates that careful clinical monitoring and possible dose adjustments are necessary.


Q: Can Zodol affect my blood pressure?

A: Regulatory documents indicate that Zodol may potentially cause new onset of high blood pressure (hypertension) or worsen existing high blood pressure. Regulatory information notes that blood pressure monitoring is a consideration during treatment.


Q: Can I take other over-the-counter pain relievers while using Zodol?

A: Official prescribing information strictly forbids the use of Zodol with other non-steroidal anti-inflammatory drugs (NSAIDs), including over-the-counter NSAIDs like aspirin, ibuprofen, or naproxen. This is due to a cumulative risk of serious side effects. The official documents do not list the same contraindication for non-NSAID pain relievers.


Q: Are there specific symptoms that mean I should stop taking Zodol immediately?

A: Official patient safety information describes specific signs of a serious problem that warrant immediate consultation with a healthcare provider and may lead to stopping the medication. These include symptoms of severe allergic reaction, signs of gastrointestinal bleeding (such as vomiting blood or black, tarry stools), or symptoms related to a heart attack or stroke.


Q: Can Zodol be used for dental pain?

A: The drug is officially indicated for the short-term management of moderately severe acute pain that requires strong analgesia. While this can include severe acute post-operative dental pain, the indication is broad and not limited to specific pain types.


Q: Is Zodol intended for pediatric use (children)?

A: The safety and effectiveness of Zodol have generally not been established for use in pediatric patients, meaning children and adolescents under 18 years of age. Official guidelines typically advise against its use in this population.


Q: What is Zodol used for besides pain after surgery?

A: Zodol is indicated for the short-term (not more than 5 days) treatment of moderately severe acute pain that requires a strong level of pain relief. While its use is common post-operatively, it is approved for various types of acute pain when a prescriber determines it is appropriate and necessary.


Q: How quickly does Zodol start working after taking it?

A: Official clinical pharmacology data indicates that, after taking an oral dose, the medication typically reaches its maximum concentration in the blood within approximately 44 minutes to one hour. This rapid absorption is aligned with the drug’s intended use for acute pain.


Q: How long does the effect of Zodol typically last?

A: The medication is typically administered every four to six hours as needed, which gives an indication of the expected duration of action. Official pharmacokinetic data shows that the average time it takes for half of the drug to be eliminated from the body (half-life) is approximately five to six hours in healthy young adults.


Q: Is Zodol a narcotic or an opioid?

A: No. Zodol (Ketorolac) is classified as a non-steroidal anti-inflammatory drug (NSAID). Although its potent pain relief is often compared to the analgesic level of opioids, it functions through a completely different mechanism and is chemically unrelated to narcotics or opioids.


Q: Is it normal to feel drowsy or sleepy after taking Zodol?

A: Drowsiness (somnolence) and dizziness are listed in official documents among the commonly reported central nervous system adverse reactions that have been reported with the use of Zodol.


Q: Do I need to take Zodol with food or is it okay on an empty stomach?

A: Official patient information indicates that the oral tablet form may be taken with food, a snack, or an antacid. This practice helps to lessen the potential for stomach upset and irritation, which is a known risk with NSAIDs.


Q: Is Zodol safe to use during pregnancy?

A: Official regulatory warnings strongly advise against the use of NSAIDs like Zodol starting at 20 weeks of pregnancy, and they are strictly prohibited from 30 weeks gestation onward. This is due to potential risks to the fetus, particularly involving the kidneys and the developing heart structure.


Q: Is Zodol safe to use while breastfeeding?

A: Official regulatory documents confirm that Ketorolac is excreted into breast milk. Based on this information and the potential for risk to the breastfed infant, some authorities advise that Zodol is contraindicated (prohibited) during breastfeeding.


Q: Are there any long-term risks associated with Zodol use?

A: Yes. Official regulatory documents strictly limit the total duration of treatment to no more than 5 days, regardless of the administration route. This restriction is in place because the risk of serious side effects, particularly gastrointestinal bleeding and kidney problems, is known to increase significantly with prolonged use.


Q: Can Zodol interact with supplements like fish oil or garlic?

A: Official labeling primarily lists formal drug-drug contraindications. However, the drug’s high-risk profile for affecting coagulation means that interaction potential exists with any substance, including supplements, known to have blood-thinning properties.


Q: Can Zodol cause dizziness or problems with concentration?

A: Dizziness is a commonly reported side effect in the official safety information. Problems with concentration have also been reported as a potential central nervous system effect.


Q: How is the safety profile of Zodol described in official regulatory information?

A: The safety profile is outlined by a Boxed Warning in official documents, which highlights the risk of serious cardiovascular thrombotic events (like heart attack or stroke), severe gastrointestinal bleeding, and renal (kidney) toxicity. The 5-day treatment limit is a key measure imposed to manage these serious risks.


Q: Does Zodol affect liver function?

A: Official warnings state that Zodol, like other NSAIDs, may cause an elevation in liver enzyme tests. Rare cases of severe liver reactions, including liver failure, have also been reported. For individuals with existing liver dysfunction, official documents describe caution regarding the drug’s use.


Q: Can Zodol be crushed or split if it is a tablet?

A: Regulatory documents do not provide specific instructions for physically altering the tablets. To ensure the correct dose is delivered and absorbed as intended, tablets are typically swallowed whole, unless manufacturer guidance specifically indicates they can be split or crushed.


Q: What type of anesthesia is Zodol sometimes used with?

A: Zodol is used in hospital and post-operative settings as part of a multimodal analgesia plan to manage acute pain, and it may be used in conjunction with other types of pain medication, including opioids. Official information generally contraindicates its use as a prophylactic pain reliever before any major surgery.


Q: Can Zodol cause allergic reactions?

A: Yes, allergic reactions (hypersensitivity reactions) are reported in official adverse event lists, including severe reactions such as anaphylaxis. The medication is contraindicated in patients known to be sensitive to Ketorolac, aspirin, or any other NSAID.


Q: Is Zodol used for headache or migraine relief?

A: The official indication is for moderately severe acute pain. Although some protocols may involve the use of Zodol for severe headaches or migraines, the regulatory indication remains generalized to acute pain that requires a potent non-opioid option.


Q: What is the risk of heart-related side effects with Zodol?

A: The official Boxed Warning states that NSAIDs, including Zodol, increase the risk of serious cardiovascular thrombotic events, such as myocardial infarction (heart attack) and stroke. This risk can increase the longer the medication is used, which is why the treatment duration is strictly limited.


Q: What should I do if I notice a change in my urine color while on Zodol?

A: Changes in urination patterns, dark urine, or yellowing of the skin or eyes (jaundice) are listed in patient information as symptoms that could indicate kidney or liver problems. The appearance of such symptoms is noted in regulatory information as requiring immediate medical consultation.


Q: Can Zodol affect fertility?

A: Official regulatory information indicates that Zodol, like other drugs that inhibit the body's prostaglandin synthesis, may impair fertility in women. Discontinuation of the drug is an official consideration for women who are having difficulty conceiving.


Q: Do studies show Zodol is effective for muscle pain or sprains?

A: Zodol is indicated for the short-term treatment of moderately severe acute pain. The regulatory approval is based on its demonstrated effectiveness for this overall category of pain, which may include severe acute musculoskeletal injuries like sprains.


Q: Why is Zodol not available over the counter?

A: Zodol is approved for prescription-only use due to the serious risks, including those related to the stomach, heart, and kidneys, which are highlighted in the official Boxed Warning. The strict limits on dosing and the need for medical supervision and specific patient screening require prescription control.


Q: What are the official restrictions on who can receive Zodol?

A: The medication is strictly contraindicated in patients with certain conditions, including advanced kidney impairment, active gastrointestinal bleeding or ulcers, and a high risk of any internal bleeding. It is also generally not indicated for pediatric patients and is forbidden for pre-operative use in major surgery.

How should Zodol (Ketorolac) be stored and disposed of?

Storage and Disposal Requirements

Zodol (ketorolac) must be stored and handled according to strict regulatory guidelines to maintain potency and safety.

Storage Conditions

Ketorolac tablets and ophthalmic solution must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The ophthalmic solution requires protection from light, and the liquid injectable form must not be frozen.

Tablets must be dispensed in a tight, light-resistant container equipped with a child-resistant closure.

Disposal and Safety

All forms of the medicine must be stored out of the reach of children. The nasal spray formulation must be discarded within 24 hours after the first dose is administered. Unused or expired medication must be disposed of according to local regulatory guidelines, avoiding disposal via household wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zodol (Ketorolac) found in:

A-Z Index: